Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 6/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.62 |
| ▸ | CDK8 | P49336 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31107378 | 0.85 | BRD4 (0.74) | BRD4MAP3K11LRRK2CDK8AXL | |
| SCHEMBL858100 | 0.85 | BRD4 (0.74) | BRD4MAP3K11LRRK2CDK8AXL | |
| SCHEMBL4831501 | 0.80 | CDK8 (0.81) | BRD4LRRK2CDK8AXLPIK3CD | |
| SCHEMBL415161 | 0.80 | BRD4 (0.67) | BRD4LRRK2CDK8AXLPIK3CD | |
| SCHEMBL7981608 | 0.80 | BRD4 (0.67) | BRD4FGFR1KDR | |
| SCHEMBL30173311 | 0.79 | BRD4 (0.65) | BRD4MAP3K11LRRK2CDK8AXL | |
| SCHEMBL12127570 | 0.79 | BRD4 (0.65) | BRD4CDK8AXLPIK3CDPIK3CA | |
| SCHEMBL28502161 | 0.79 | BRD4 (0.64) | BRD4MAP3K11LRRK2CDK8AXL | |
| SCHEMBL14620778 | 0.78 | BRD4 (0.63) | BRD4MAP3K11LRRK2CDK8AXL | |
| SCHEMBL414175 | 0.78 | BRD4 (0.63) | BRD4MAP3K11LRRK2CDK8AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050075-B | Biaryl ring BET inhibitor and synthetic method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117050075-A | Biaryl ring BET inhibitor and synthetic method and application thereof | 中国药科大学 | 2023-11-14 | — | — | CN | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-9814704-B2 | Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors | THE UNIVERSITY OF ROCHESTER (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF ROCHESTER | 2016-11-03 | — | — | US | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103153994-A | Bicyclic heteroaryl kinase inhibitors and methods of use | UNIV ROCHESTER | 2013-06-12 | — | — | CN | disclosed |
| EP-2576549-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | University of Rochester (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149950-A2 | BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-102264743-A | Mlk inhibitors and methods of use | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2379561-A2 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068483-A2 | MLK INHIBITORS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053175-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885MAP3K11 23/4885LRRK2 397/4885 |
| US-20160317509-A1 | MLK INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K2, MAP3K7 | BRD4 806/4885MAP3K11 23/4885LRRK2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.